NCM · Biotechnology

PCSA (PCSA) Stock

$2.81 +8.49% NCM: PCSA Healthcare

Valuation

MetricValue
Price$2.81
Market Cap$7.78M
P/E Ratio-0.28
P/B Ratio1.31
P/S Ratio0.00
EPS (TTM)$-10.36
52-Week High$14.25
52-Week Low$1.76
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-233.33%
ROA-175.00%
ROCE-233.33%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio3.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-12.0M$-28.0M$-11.0M$-12.0M$-14.0M
Net Profit$-11.0M$-27.0M$-11.0M$-12.0M$-14.0M
EPS$-373.00$-851.19$-212.00$-96.75$-10.36
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$26.0M$9.0M$6.0M$3.0M$8.0M
Total Liabilities$1.0M$1.0M$1.0M$2.0M$2.0M
Cash$16.0M$7.0M$5.0M$1.0M$6.0M
Borrowings$0$0$0$0$0

Latest News

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline InvestorsHub · Jul 29, 2026 PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS GlobeNewswire · Jul 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$-10.0M$-8.0M$-11.0M$-11.0M
Investing Cash Flow$0$0$0$0$-1.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$1.0M$-10.0M$-2.0M$-4.0M$4.0M
Free Cash Flow$-9.0M$-10.0M$-8.0M$-11.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-139.93%
Quick Ratio3.00
Interest Coverage—
Return 1Y-53.37%
Return 3Y-98.97%
Return 5Y-99.93%

Ownership

Insiders Held14.90%
Institutions Held10.24%
Institutions Float Held12.03%
Institutional HolderSharesReport Date
Connective Capital Management LLC70,7362026-03-31
Stonepine Capital Management, LLC55,0002026-03-31
Geode Capital Management, LLC24,9082026-03-31
Vanguard Capital Management LLC12,7292026-03-31
Vanguard Fiduciary Trust Co10,8572026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLR $1.39 -0.71% -1.91 $22.12M 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%
BCTX $3.53 +1.73% -0.04 $6.65M 0.00%
CRIS $4.69 -4.09% -0.35 $9.14M 0.00%
CTXR $0.57 -9.81% -0.68 $6.37M 0.00%

About PCSA

PCSA is led by CEO George K. Ng, employs 10 people, headquartered in US, publicly traded since 2014.

PCSA stock trades at $2.81 with a market capitalization of $7.78M. The stock is valued at a price-to-earnings (P/E) ratio of -0.28, price-to-book of 1.31, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.76 and $14.25, and currently trades 80.3% below its 52-week high.

On profitability, PCSA generates a return on equity (ROE) of -233.33%, return on capital employed of -233.33%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides